Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Prossimi studi clinici
-
Seoul National University HospitalSamil Pharmaceutical Co., Ltd.ReclutamentoSarcopenia | Protesi totale di ginocchioCorea del Sud
-
Stanford UniversityNon ancora reclutamentoLeucemia mieloide acuta | Sindromi mielodisplastiche | Neoplasia mieloproliferativaStati Uniti
-
Cheng QiReclutamento
-
Stanford UniversityNon ancora reclutamentoInsufficienza epaticaStati Uniti
-
Istanbul Aydın UniversityNon ancora reclutamentoDolore al collo | Sindrome da dolore miofasciale | Disturbi muscoloscheletrici legati al lavoroTurchia (Türkiye)
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Non ancora reclutamentoCarcinoma endometriale ricorrente | Carcinoma endometriale avanzato | Carcinoma endometriale metastatico | Cancro dell'endometrio in stadio III | Cancro dell'endometrio in stadio IVStati Uniti
-
University of Colorado, DenverReclutamentoScoliosi idiopatica adolescenziale (AIS) | Scoliosi neuromuscolareStati Uniti
-
University of FloridaAmerican Heart AssociationReclutamentoScompenso cardiaco con frazione di eiezione conservata (HFPEF)Stati Uniti
-
UNC Lineberger Comprehensive Cancer CenterNon ancora reclutamentoLeucemia | Leucemia linfoblastica acuta | Linfoma linfoblastico | Leucemia acuta | Leucemia linfoide acutaStati Uniti
-
Korea University Anam HospitalThe Catholic University of Korea; Keimyung University Dongsan Medical Center; Medical...Non ancora reclutamentoCancro urologico | Lesione miocardica dopo chirurgia non cardiaca | Principali eventi cardiovascolari avversi (MACE)
-
Montefiore Medical CenterNon ancora reclutamentoCesarean Scar Defect (Isthmocele)Stati Uniti
-
SanofiNon ancora reclutamento
Clinical Research Jobs
-
Philippines - Manila
-
Taiwan - Taipei
-
United States - Shrewsbury
-
Germany - Munich
-
Germany - Nordrhein-Westfalen - CologneAustria
-
Serbia - Belgrade
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China